Sharma et al., 2023 - Google Patents
Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseasesSharma et al., 2023
View HTML- Document ID
- 6710749874998019774
- Author
- Sharma D
- Zachary I
- Jia H
- Publication year
- Publication venue
- Investigative Ophthalmology & Visual Science
External Links
Snippet
Purpose: The purpose of this study was to evaluate clinical reports of response-loss in patients with neovascular eye diseases, such as neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), after repeated anti-vascular …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sharma et al. | Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases | |
| Fogli et al. | Clinical pharmacology of intravitreal anti-VEGF drugs | |
| Zhao et al. | Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration | |
| Cao et al. | Targeting angiogenesis in oncology, ophthalmology and beyond | |
| Ciulla et al. | Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration | |
| Sene et al. | Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye | |
| Kubasch et al. | Development of luspatercept to treat ineffective erythropoiesis | |
| Arima et al. | Claudin-5 redistribution induced by inflammation leads to anti-VEGF–resistant diabetic macular edema | |
| McCloskey et al. | Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity | |
| Razani-Boroujerdi et al. | T cells express α7-nicotinic acetylcholine receptor subunits that require a functional TCR and leukocyte-specific protein tyrosine kinase for nicotine-induced Ca2+ response | |
| Yang et al. | VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis | |
| Costagliola et al. | Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration | |
| Tate et al. | LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo*[S] | |
| Chen et al. | Transforming growth factor β1 (TGF-β1) activates hepcidin mRNA expression in hepatocytes | |
| Hobbs et al. | TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells | |
| Zamora et al. | Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy | |
| Matsuo et al. | Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models | |
| Sun et al. | Epithelial membrane protein 2 (EMP2) promotes VEGF-induced pathological neovascularization in murine oxygen-induced retinopathy | |
| Zehetner et al. | Systemic upregulation of PDGF-B in patients with neovascular AMD | |
| Barnett et al. | Endoglin promotes angiogenesis in cell-and animal-based models of retinal neovascularization | |
| Santarelli et al. | Advances in pharmacotherapy for wet age-related macular degeneration | |
| Zhou et al. | Imatinib ameliorated retinal neovascularization by suppressing PDGFR-α and PDGFR-β | |
| Zehetner et al. | Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy | |
| Bucher et al. | Antibody-mediated inhibition of Tspan12 ameliorates vasoproliferative retinopathy through suppression of β-catenin signaling | |
| Yun et al. | Angiopoietin 1 attenuates interleukin-6-induced endothelial cell permeability through SHP-1 |